1. Home
  2. ARVN vs OPTU Comparison

ARVN vs OPTU Comparison

Compare ARVN & OPTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.95

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Logo Optimum Communications Inc. Class A common stock

OPTU

Optimum Communications Inc. Class A common stock

N/A

Current Price

$0.69

Market Cap

315.0M

ML Signal

N/A

Company Overview

Basic Information
Metric
ARVN
OPTU
Founded
2015
2015
Country
United States
United States
Employees
N/A
9500
Industry
Biotechnology: Pharmaceutical Preparations
Cable & Other Pay Television Services
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
315.0M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ARVN
OPTU
Price
$8.95
$0.69
Analyst Decision
Buy
Hold
Analyst Count
19
3
Target Price
$15.05
$1.75
AVG Volume (30 Days)
858.9K
4.2M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.06
$0.59
52 Week High
$14.22
$2.14

Technical Indicators

Market Signals
Indicator
ARVN
OPTU
Relative Strength Index (RSI) 37.05 30.58
Support Level $8.72 N/A
Resistance Level $10.18 $1.97
Average True Range (ATR) 0.47 0.10
MACD 0.00 -0.01
Stochastic Oscillator 28.82 18.33

Price Performance

Historical Comparison
ARVN
OPTU

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About OPTU Optimum Communications Inc. Class A common stock

Optimum's assets were brought together when Altice Europe acquired US cable companies Suddenlink in 2015 and Cablevision in 2016. The Suddenlink business, which management calls the "West," provides television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. The Cablevision portion, dubbed the "East," provides comparable services to about 5.5 million homes and businesses in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Optimum, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018.

Share on Social Networks: